News & Updates

Show Multimedia Only

Pain linked to balance, gait issues in COPD

08 May 2025

Individuals with chronic obstructive pulmonary disease (COPD) appear to have poor balance and slower gait speed in the presence of pain, according to a study.

Pain linked to balance, gait issues in COPD

08 May 2025

KRAS-mutant advanced NSCLC responds to fulzerasib–cetuximab combo

07 May 2025 by

First-line treatment with the combination of fulzerasib and cetuximab appears to induce deep and durable responses in patients with advanced nonsmall cell lung cancer (NSCLC) harbouring KRAS G12C mutation, in addition to having a favourable safety profile, according to the results of the phase II, open-label, single-arm KROCUS trial.

KRAS-mutant advanced NSCLC responds to fulzerasib–cetuximab combo

07 May 2025

Rapid point-of-care testing enables timely and targeted RTI treatment

07 May 2025

According to the 2021 Global Burden of Disease (GBD) study, COVID-19 and lower respiratory tract infections (LRTIs) ranked as the 1st and 5th leading causes of global disease burden across all age groups and genders.

Rapid point-of-care tests (POCTs) enable timely diagnosis, particularly in vulnerable populations at higher risk of severe illness, complications, and hospitalization.

Rapid point-of-care testing enables timely and targeted RTI treatment

07 May 2025

Single-dose RSVPreF3 OA vaccine effective over 3 RSV seasons in seniors

07 May 2025 by

A single dose of adjuvanted respiratory syncytial virus (RSV) prefusion F protein–based vaccine (RSVPreF3 OA) is efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) over three RSV seasons in older adults aged ≥60 years, according to results of the phase III AReSVi-006 trial presented at ESCMID Global 2025.

Single-dose RSVPreF3 OA vaccine effective over 3 RSV seasons in seniors

07 May 2025

Redefining COPD care with dupilumab

05 May 2025

During the Singapore launch event hosted by Sanofi for dupilumab, experts discussed the evolving role of immunobiologicals in managing chronic obstructive pulmonary disease (COPD). Internationally renowned pulmonologist Professor Klaus Rabe, The LungenClinic Grosshansdorf & Christian Albrecht University of Kiel, Grosshansdorf, Germany, delivered a keynote lecture. This was followed by a clinically focused panel discussion moderated by Associate Professor Augustine Tee from Changi General Hospital, Singapore, with insights from Assistant Professor Tiew Pei Yee (Singapore General Hospital) and Dr Xu Huiying (Tan Tock Seng Hospital).

Redefining COPD care with dupilumab

05 May 2025

Therapeutic thoracentesis of no help in patients with acute heart failure, pleural effusion

04 May 2025

A strategy of upfront routine thoracentesis in addition to standard medical therapy does not appear to improve survival outcomes for patients with acute heart failure and pleural effusion, as shown in the results of TAP-IT*.

Therapeutic thoracentesis of no help in patients with acute heart failure, pleural effusion

04 May 2025

Ibrexafungerp expands salvage antifungal treatment options as a pill

03 May 2025 by

For patients with fungal diseases that preclude receiving standard treatment or IV antifungals primarily due to refractoriness or resistance, ibrexafungerp can serve as an effective salvage treatment given orally, offering a positive risk-benefit ratio up to the final data cut-off in the FURI trial

Ibrexafungerp expands salvage antifungal treatment options as a pill

03 May 2025

Breastfeeding reduces risk of infant RTIs

02 May 2025

Infants who have been fully breastfed for 6 months up to at least 1 year appear to have a lower risk of subsequent respiratory tract infections (RTIs) and hospitalization from RTIs, a study has shown.

Breastfeeding reduces risk of infant RTIs

02 May 2025

MSC therapy delivers long-term benefit in severe COVID-19

02 May 2025 by

A recent study suggests patients with severe COVID-19 may benefit from human mesenchymal stem cell (MSC) therapy.

MSC therapy delivers long-term benefit in severe COVID-19

02 May 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025

02 May 2025

New drug applications approved by US FDA as of 1-15 April 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025

02 May 2025

News & Updates

Showing Respirology articles

Showing

Specialty:

Pain linked to balance, gait issues in COPD

Pain linked to balance, gait issues in COPD

KRAS-mutant advanced NSCLC responds to fulzerasib–cetuximab combo

KRAS-mutant advanced NSCLC responds to fulzerasib–cetuximab combo

Rapid point-of-care testing enables timely and targeted RTI treatment

Rapid point-of-care testing enables timely and targeted RTI treatment

Single-dose RSVPreF3 OA vaccine effective over 3 RSV seasons in seniors

Single-dose RSVPreF3 OA vaccine effective over 3 RSV seasons in seniors

Redefining COPD care with dupilumab

Redefining COPD care with dupilumab

Therapeutic thoracentesis of no help in patients with acute heart failure, pleural effusion

Therapeutic thoracentesis of no help in patients with acute heart failure, pleural effusion

Ibrexafungerp expands salvage antifungal treatment options as a pill

Ibrexafungerp expands salvage antifungal treatment options as a pill

Breastfeeding reduces risk of infant RTIs

Breastfeeding reduces risk of infant RTIs

MSC therapy delivers long-term benefit in severe COVID-19

MSC therapy delivers long-term benefit in severe COVID-19

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025